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The association of copper (Cu) defi  ciency with 
cardiomyopathy and other forms of cardiac 
  disease has been recognized for a long time (1), 
but its clinical signifi  cance has not been fully 
explored. The current US-Canadian Recom-
mended Dietary Allowance (RDA) for Cu is 
0.9 mg/day with a tolerable upper intake level 
of 10 mg/day for adults 19 years of age or older 
(2). A debate continues regarding the appropri-
ateness of the RDA for Cu (3). A human study 
has examined the potential adverse eff  ects of 
marginal dietary Cu restriction on the cardio-
vascular system (4). Among 24 subjects con-
suming a typical American diet (1.03 mg Cu/day), 
four subjects suff  ered from cardiac complica-
tions after consuming the diet for 4–10 wk. 
In this case, preexisting cardiac conditions can-
not be excluded; however, the fact that these 
abnormalities appeared after the subjects were 
fed the controlled low Cu diet does suggest a 
detrimental eff  ect of low levels of Cu. More-
over, these cardiac defects disappeared after 
the aff  ected subjects were supplemented with 
3.0 mg Cu/day (4).
An early study of hearts from people who 
died from ischemic heart disease showed that Cu 
concentrations were decreased in the un  injured 
tissues of the infarcted hearts relative to normal 
heart tissues (5). Another study showed that Cu 
concentrations decreased in the hearts of people 
who died from acute ischemic infarction (6). The 
death rate from ischemic heart dis  ease in soft wa-
ter areas was found to be increased, and Cu concen-
trations were lower in the hearts of people who 
died from chronic ischemic heart disease (7, 8).
Cu supplementation can reverse   hypertrophic 
cardiomyopathy in some patients. One example 
of this is a rare congenital condition of Sco2 
mutations, which aff  ects Cu   metabolism and 
predisposes to hypertrophic cardiomyopathy. 
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Sustained pressure overload causes cardiac hypertrophy and the transition to heart failure. 
We show here that dietary supplementation with physiologically relevant levels of copper 
(Cu) reverses preestablished hypertrophic cardiomyopathy caused by pressure overload 
induced by ascending aortic constriction in a mouse model. The reversal occurs in the 
continued presence of pressure overload. Sustained pressure overload leads to decreases in 
cardiac Cu and vascular endothelial growth factor (VEGF) levels along with suppression of 
myocardial angiogenesis. Cu supplementation replenishes cardiac Cu, increases VEGF, and 
promotes angiogenesis. Systemic administration of anti-VEGF antibody blunts Cu regression 
of hypertrophic cardiomyopathy. In cultured human cardiomyocytes, Cu chelation blocks 
insulin-like growth factor (IGF)-1– or Cu-stimulated VEGF expression, which is relieved by 
addition of excess Cu. Both IGF-1 and Cu activate hypoxia-inducible factor (HIF)-1𝗂 and 
HIF-1𝗂 gene silencing blocks IGF-1– or Cu-stimulated VEGF expression. HIF-1𝗂 coimmuno-
precipitates with a Cu chaperone for superoxide dismutase-1 (CCS), and gene silencing of 
CCS, but not superoxide dismutase-1, prevents IGF-1– or Cu-induced HIF-1𝗂 activation 
and VEGF expression. Therefore, dietary Cu supplementation improves the condition of 
hypertrophic cardiomyopathy at least in part through CCS-mediated HIF-1𝗂 activation 
of VEGF expression and angiogenesis.
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Sco2 is an important Cu chaperon for cytochrome c oxidase 
(CCO), and mutations in Sco2 result in suppressed CCO ac-
tivity (9). Patients with mutations in Sco2 developed severe 
hyper  trophic cardiomyopathy (9). A SCO2 patient with severe 
hypertrophic cardiomyopathy was treated with Cu-histidine. 
This Cu supplement therapy caused reversal of the hyper-
trophic cardiomyopathy along with signifi  cant improvement 
in all parameters of heart function and normalization of ECG 
signs and blood pressure (10). A recent study in a small popu-
lation of chronic heart failure patients has shown that dietary 
supplementation with micronutrients for 9 mo increases left 
ventricle ejection and decreases left ventricle volume along 
with improvement of quality of life (11). Among the formu-
lated micronutrients in this study was Cu (1.2 mg/day).
To provide a scientifi  c basis for Cu supplementation-
  induced regression of hypertrophic cardiomyopathy, we used 
a mouse model of cardiac hypertrophy and dysfunction pro-
duced by ascending aortic constriction. In the present study, 
we found that dietary supplementation with physiologically 
relevant levels of Cu reverses cardiac hypertrophy and dysfunc-
tion even in the presence of chronic pressure overload. The 
cardiac eff  ect of dietary Cu supplementation is associated with 
restoration of normal vascular epithelial growth factor (VEGF) 
expression and enhanced angiogenesis. In the presence of anti-
VEGF antibody, dietary Cu supplementation failed to reverse 
the preestablished heart hypertrophy and dysfunction. We fur-
ther found that Cu is required for hypoxia-inducible factor 
(HIF)-1α transcription activity, which requires the Cu chap-
eron for superoxide dismutase-1 (CCS) for activation of VEGF 
expression. These results suggest that dietary Cu supplementa-
tion can improve the condition of hypertrophic cardiomyopathy 
through, at least in part, CCS-mediated activation of HIF-1α 
transcription factor for VEGF gene expression.
RESULTS
Regression of cardiac hypertrophy and dysfunction 
by Cu supplementation
We subjected adult (10–12 wk old) male C57BL/6J mice to 
chronic pressure overload generated by ascending aortic con-
striction (AAC) along with sham surgery controls. In mice fed 
a diet containing RDA adequate levels of Cu (6 mg Cu/kg), 
cardiac hypertrophy was observed as measured by the increase 
in heart weight to body weight ratio, by direct observation of 
the gross anatomy of the heart, and from echocardiography 
including increases in left ventricle end systolic diameter and 
posterior wall thickness 4 or 8 wk after AAC surgery (Fig. 1). 
Cu supplementation (20 mg Cu/kg) during the last 4 wk sig-
nifi  cantly reversed cardiac hypertrophy (Fig. 1). AAC caused 
cardiac contractile dysfunction in mice fed 6 mg Cu/kg diet 
for 4 wk as measured by the percentage of fractional shorten-
ing (Fig. 1, %FS) and ejection fraction (Fig. 1, EF) using 
echocardiography. These mice underwent the transition to 
heart failure at 8 wk after AAC as indicated by further de-
creases in %FS and EF and a signifi  cant increase in the lung 
weight to body weight ratio. Cu supplementation completely 
Figure 1.  Cu supplementation–induced recovery of cardiac 
hypertrophy and dysfunction in mice subjected to AAC and fed 
6 mg Cu/kg diet (6 ppm). 4 wk after AAC surgery, some mice were 
kept on the same diet for another 4 wk (8 wks) and others changed to 
20 mg/Cu/kg diet (6/20 ppm) for 4 wk. (A) Gross anatomic changes of 
the hearts. (B) Representative M mode recordings of echocardiography 
of left ventricles (LV). The LV dimensions at end systole (fi  rst vertical 
line) and at end diastole (second vertical line) were increased at the 
end of 4 wk after AAC, and further dilation occurred 8 wk after AAC, 
indicating heart failure. (C) Heart weight to body weight ratio (HW/BW, 
mg/g); lung weight to body weight (LW/BW, mg/g); the quantitative 
analysis of the recordings from echocardiograph, including the per-
centage of fractional shortening (%FS); ejection fraction (EF); left 
  ventricle end-systolic diameter (LVESD); and posterior wall thickness 
(PWT). *, Signifi  cantly different from sham-operated controls (P < 0.05, 
n = 6–12). #, Signifi  cantly different from AAC-treated mice fed 6 ppm 
Cu diet for 4 wk (P < 0.05, n = 6–12).JEM VOL. 204, March 19, 2007  659
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reversed the contractile dysfunction and prevented the transi-
tion to heart failure (Fig. 1).
Histological sections showed cellular hypertrophy along 
with degenerative morphological changes including necrosis 
and fi  brosis in mice subjected to AAC and fed 6 mg Cu/kg 
diet for 4 wk, and more severe pathological changes were 
observed in mice fed the same diet for 8 wk (Fig. 2). Electron 
microscopic examination revealed mitochondrial abnormal-
ities including swelling, structural disruption, membrane rup-
ture, and the appearance of amorphous matrix densities in mice 
fed 6 mg Cu/kg diet for 8 wk (Fig. 2). In mice fed 20 mg 
Cu/kg diet during the last 4 wk after AAC surgery, cardiac 
pathological changes including   necrosis, fi  brosis, and ultra-
structural abnormalities were all eliminated (Fig. 2). These 
results thus demonstrate that dietary Cu supplementation re-
verses preestablished hypertrophic cardiomyopathy induced 
by chronic pressure overload even in the continued presence 
of the pathological stimulus.
Cu supplementation restores VEGF levels and promotes 
angiogenesis in pressure overload hearts
The capillary density in the myocardium subjected to AAC 
for 4 or 8 wk was signifi  cantly decreased in mice fed 6 mg 
Cu/kg diet. However, cardiac VEGF levels were signifi  cantly 
increased 4 wk after AAC, but signifi  cantly decreased 8 wk 
after AAC in mice fed 6 mg Cu/kg. Dietary Cu supplemen-
tation during the last 4 wk after AAC restored VEGF levels 
and increased the capillary density in the heart in spite of the 
continued presence of pressure overload (Fig. 3).
Cu concentrations decrease in hearts subjected 
to pressure overload
The total levels of Cu in the hearts of mice subjected to AAC 
and fed 6 mg Cu/kg diet for 4 wk signifi  cantly decreased. 
Dietary Cu supplementation for 4 wk, started at   either the 
same time with AAC surgery or 4 wk after feeding 6 mg Cu/kg 
diet, eff  ectively prevented or reversed Cu   depletion in the 
heart (Fig. 3). Cu supplementation did not change cardiac Cu 
levels in the sham controls (Fig. 3). To determine the func-
tional signifi  cance of Cu depletion in the heart, the activity of 
a most sensitive Cu-dependent enzyme complex, cytochrome 
c oxidase (CCO) was measured. As shown in Fig. 3, CCO activ-
ity was signifi  cantly depressed 4 wk after AAC and f  urther 
decreased 8 wk (although not signifi  cantly diff  erent from 4 wk) 
after AAC surgery. CCO activity was completely restored 
4 wk after Cu supplementation.
Figure 2.  Cu supplementation–induced recovery of morphological 
abnormalities in mice subjected to AAC and fed 6 ppm Cu diet for 
4 wk. Cardiac morphology changes were observed by cross section (C/S), 
histopathological changes including necrosis (hematoxylin and eosin [H/E]), 
fi  brosis stained by Sirius red (SR), and increased cell size observed by 
wheat germ agglutinin (WGA) staining for cell membrane. EM revealed 
swelling (arrows), structural disruption (asterisks), and membrane rupture 
(arrowhead) in mitochondria. All of these changes were much more severe 
at 8 wk but were eliminated by dietary Cu supplementation during the last 
4 wk (6/20 ppm) after AAC surgery. Insert in the EM image at 8 wk shows 
amorphous matrix densities (AMD), a specifi  c severe damage to mito-
chondria. Bars: 50 μm (H/E, SR, and WGA panels); 1.5 μm (EM panels).660  COPPER REVERSAL OF HYPERTROPHIC CARDIOMYOPATHY | Jiang et al.
Anti-VEGF antibody blunts Cu supplementation-induced 
regression of hypertrophic cardiomyopathy
We investigated whether or not restoration of myocardial 
VEGF levels and the associated angiogenesis might be in-
volved in dietary Cu supplementation-induced regression of 
cardiac hypertrophy and dysfunction by using anti-VEGF 
  antibody. At the time when mice with established cardiac 
hypertrophy and dysfunction were switched from 6 mg Cu/kg 
diet to 20 mg Cu/kg diet, they were injected intravenously 
with anti-VEGF antibody every 3 d for 27 d. This treatment 
completely blunted Cu supplementation-induced regression 
of hypertrophic cardiomyopathy. The treatment with anti-
VEGF antibody aff   ected neither cardiac morphology nor 
contractile function of the sham controls (Fig. 4). This result 
thus suggests that dietary Cu supplementation-induced reversal 
of heart hypertrophy and dysfunction is mediated at least in 
part by restoration of myocardial VEGF expression and the 
associated angiogenesis.
Cu requirement for HIF-1𝗂 activation of VEGF expression
Because HIF-1α is a critical transcription factor for VEGF 
expression, we examined the eff  ect of the Cu chelator, tetra-
ethylenepentamine pentahydrochloride (TEPA), on HIF-1α 
transcription activation in cultured human cardiomyocytes. 
HIF-1α activation was induced by insulin-like growth factor 
(IGF)-1, a well-known growth factor stimulating VEGF pro-
duction by activating HIF-1α, in comparison with the stimu-
latory eff  ect of Cu. Both IGF-1 and Cu activated HIF-1α 
and stimulated VEGF expression. Importantly, TEPA blocked 
both the stimulatory eff  ect of IGF-1 and that of Cu (Fig. 5), 
Figure 3.  Effect of Cu supplementation on AAC-suppressed VEGF, 
angiogenesis, and cardiac Cu concentrations. (A) Myocardial capillary 
density detected by CD31 staining. Bars, 50 μm. (B) Quantitative analysis 
of capillary density using a computer-assisted image analyzer (SigmaScan 
Pro5.0; SPSS, Inc.). Three fi  elds at 200× magnifi  cation per heart were analyzed 
and six mice in each group were examined for the calculation. (C) Western blot 
analysis of VEGF levels in the heart tissue. (D) AAC-induced decreases in cardiac 
Cu concentrations 4 wk after AAC and the effect of Cu supplementation. 
(E) AAC-induced depression of cardiac CCO activity (CCO/CS ratio) 4 or 
8 wk after AAC and the effect of Cu supplementation. *, Signifi  cantly different 
from sham-operated controls (P < 0.05, n = 6). #, Signifi  cantly different 
from AAC-treated mice fed 6 ppm Cu diet for 4 wk (P < 0.05, n = 6).JEM VOL. 204, March 19, 2007  661
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suggesting a requirement for Cu in HIF-1α activation of 
VEGF expression. To further test the requirement of Cu for 
VEGF expression, varying concentrations of CuSO4 were 
added into the cultures containing TEPA, and Cu dose de-
pendently relieved TEPA-mediated suppression of VEGF 
expression (Fig. 6), demonstrating that the inhibitory eff  ect 
of TEPA acted through Cu chelation. Furthermore, we de-
termined the requirement of HIF-1α for IGF-1– or Cu-
stimulated VEGF expression. We used a siRNA targeting 
HIF-1α and found that in the absence of HIF-1α, neither Cu 
nor IGF-1 stimulated VEGF expression in cultured human 
cardiomyocytes (Fig. 7).
CCS is involved in the interaction between Cu and HIF-1𝗂
The Cu chaparone CCS is involved in the synthesis of active 
Cu,Zn-SOD (SOD1) by inserting Cu to the apoprotein. We 
next examined whether or not Cu activation of HIF-1α is 
also mediated by CCS. We used an anti-CCS antibody to 
Figure 4.  Effect of anti-VEGF antibody administration on Cu 
supplementation–induced regression of cardiac morphological 
changes and contractile dysfunction. Mice were fed 6 mg Cu/kg 
diet (6 ppm) for 4 wk after AAC surgery and then were changed to 
20 mg Cu/kg diet for the last 4 wk in the presence of anti-VEGF 
  antibody administration once every 3 d. All of the parameters and 
labels are the same as presented in Fig. 1 and 2. *, Signifi  cantly different 
from sham-operated controls (P < 0.05, n = 6). C/S, cross section; H/E, 
hematoxylin and eosin; SR, Sirius red; WGA, wheat germ agglutinin. 
Bars, 50 μm.662  COPPER REVERSAL OF HYPERTROPHIC CARDIOMYOPATHY | Jiang et al.
perform an immunoprecipitation assay and found that CCS 
coimmunoprecipitated with HIF-1α (Fig. 8). To explore the 
role of CCS in HIF-1α activation and VEGF expression, we 
used a siRNA targeting CCS to delete CCS in cultured 
  human cardiomyocytes. In the absence of CCS, neither Cu 
nor IGF-1 activated HIF-1α or stimulated VEGF expression 
(Fig. 8), demonstrating the requirement for CCS in Cu-
  mediated activation of HIF-1α transcription activity for VEGF 
expression. Because CCS also transfers Cu to SOD1, we next 
used a siRNA targeting SOD1 to eliminate the possibility 
that the Cu eff  ect on VEGF expression is mediated by SOD1. 
The results, shown in Fig. 9, demonstrate that in the absence 
of SOD1, Cu- or IGF-1–stimulated VEGF expression was 
not suppressed, but in contrary, it was further stimulated.
DISCUSSION
In the present study, we report for the fi  rst time that Cu sup-
plementation actually reverses hypertrophic cardiomyopathy 
induced by chronic pressure overload. The results demon-
strate that pressure overload generated by AAC causes a 
  decrease in Cu levels in the heart along with hypertrophic 
cardiomyopathy and the transition to heart failure in mice 
fed a diet containing RDA adequate levels of Cu. The most 
important fi  nding is that Cu supplementation to mice with 
preestablished cardiac hypertrophy and dysfunction in the 
presence of sustained pressure overload signifi  cantly reduced 
heart hypertrophy and completely restored cardiac contrac-
tile function. Cardiac dysfunction is associated with decreased 
VEGF levels and inhibition of coronary angiogenesis, as 
demonstrated in previous studies (12,13). Cu supplementa-
tion increases VEGF levels and promotes angiogenesis in hy-
pertrophic hearts. VEGF plays a crucial role in the regression, 
as demonstrated by the observation that anti-VEGF antibody 
blocked Cu supplementation-induced angiogenesis and regres-
sion of hypertrophic cardiomyopathy.
Regression of preestablished hypertrophic cardiomyopa-
thy has been shown recently using the phosphodiesterase-5A 
inhibitor, sildenafi  l (14). Our present results indicate that 
  dietary Cu supplementation should be as eff  ective as oral ad-
ministration of sildenafi  l in reversing heart hypertrophy and 
dysfunction induced by chronic pressure overload. However, 
the simple and inexpensive dietary Cu supplementation 
would have obvious advantages over sildenafi  l. In particular, 
the level of the supplemented Cu is within the physiologic 
Figure 5.  Effect of the Cu chelator TEPA on Cu- and IGF-1–
induced HIF-1𝗂 activation and VEGF expression and the role of 
HIF-1𝗂 in Cu- and IGF-1–induced VEGF expression in cultured human 
cardiomyocytes. (A) The effect of TEPA on IGF-1– and Cu-induced HIF-1α 
transcription activity by ELISA assay. (B) The effect of TEPA on IGF-1– 
and Cu-induced VEGF expression by ELISA assay. Cells were cultured in 
the presence or absence of TEPA for 24 h before being exposed to IGF-1 
or Cu for 16 h. Values are mean ± SD (n = 6), and the experiment was 
repeated two times with consistent results. *, Signifi  cantly different from 
untreated controls (P < 0.05, n = 6). #, Signifi  cantly different from cor-
responding no-TEPA treated cultures (P < 0.05, n = 6).
Figure 6.  Effect of excess Cu on TEPA-suppressed VEGF expression 
induced by Cu. Cells were cultured in the presence of 25 μM TEPA for 
24 h before addition of Cu at different concentrations as indicated for 16 h. 
Values are mean ± SD (n = 6), and the experiment was repeated two 
times with consistent results. *, Signifi  cantly different from untreated 
controls (P < 0.05, n = 6).
Figure 7.  Effects of HIF-1𝗂 siRNA on IGF-1– or Cu-induced VEGF 
expression. Western blot analysis shows that treatment with HIF-1α 
siRNA for 48 h silenced CoCl2-induced HIF-1α expression but mismatched 
siRNA (MMsiRNA) did not. After being treated with the HIF-1α siRNA for 
48 h, the cells were treated with IGF-1 or Cu for 16 h and VEGF levels in 
culture media were analyzed by ELISA assay and normalized by cell numbers. 
Values are mean ± SD (n = 6), and the experiment was repeated two 
times with consistent results. *, Signifi  cantly different from mismatched 
RNA only treated (B) controls (P < 0.05, n = 6). #, Signifi  cantly different 
from corresponding treated cultures (P < 0.05, n = 6).JEM VOL. 204, March 19, 2007  663
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range and well below the maximum tolerable daily intakes 
(10 mg/day), so that it does not raise safety concerns and 
should not have the side eff  ects (e.g., headache, fl  ushing, and 
vision abnormalities) sometimes associated with sildenafi  l 
  administration. The level of Cu supplementation used in the 
present study would be equivalent to 2.9 mg/day for hu-
mans, which can be found if conventional multiple mineral 
and vitamin supplements are used (2 mg Cu/day from the 
supplement plus RDA of 0.9 mg Cu/day).
Our fi  ndings are of clinical interest in multiple ways. (a) 
Given the high prevalence of hypertrophic cardiomyopathy, 
amelioration of these conditions by simply increasing dietary 
intakes of Cu would be practical and very attractive. (b) Mar-
ginal dietary Cu restriction in humans, defi  ned as consumption 
of a diet containing less Cu than the RDA, has been identifi  ed 
from surveys of food consumption (15–17). This would ad-
versely aff  ect those in the population with cardiac   complications. 
Therefore, it appears reasonable to monitor Cu intakes for 
these populations. (c) The current RDA for Cu has not con-
sidered the special case of individuals with cardiac   complications. 
The data obtained here demonstrate that functional defi  ciency 
of Cu may occur in these populations and a diff  erent RDA for 
Cu for these populations should be considered. (d) Cu chela-
tion therapy for cancers has recently been in clinical trials (18), 
but the potential adverse eff  ects of Cu chelation on patients 
with heart disease need to be evaluated.
An important question is how Cu supplementation 
causes reversal of hypertrophic cardiomyopathy. We believe 
that one viable possibility is the eff  ect of Cu on the synthesis 
of VEGF. A recent study has demonstrated that a lack of co-
ordination between cardiac hypertrophy and angiogenesis 
(caused by suppression of VEGF activity) is associated with 
the progression of cardiac hypertrophy to heart failure (12). 
Acute phase of adaptive cardiac growth is associated with en-
hanced myocardial VEGF expression, coronary angiogenesis, 
and preservation of cardiac contractile function. Chronic and 
pathological hypertrophy is associated with depression of 
VEGF production and reduced angiogenesis (12). The study 
has defi  ned that the decrease in VEGF levels is associated 
with the switching from adaptive to pathological hyper  trophy 
under stress conditions (12). In the present study, we also 
  observed that VEGF production was increased in the early 
phase, but decreased in the late phase of cardiac hypertrophy 
induced by sustained pressure overload. However, Cu sup-
plementation restored VEGF production in the late phase of 
cardiac hypertrophy even in the continued presence of pres-
sure overload.
Figure 8.  Effect of CCS on Cu- or IGF-1–induced HIF-1𝗂 activa-
tion and VEGF expression. (A) Coimmunoprecipitation of CCS and 
HIF-1α. Human cardiomyocytes were treated with CoCl2 for 16 h to stimulate 
HIF-1α expression, as indicated. The cell extracts were immunoprecipitated 
by anti-CCS antibody (Santa Cruz Biotechnology, Inc.) and separated on 
10% SDS-PAGE gel and immunoblotted with anti–HIF-1α antibody 
(Santa Cruz Biotechnology, Inc.) and anti-CCS antibody. (B) Effects of CCS 
siRNA on IGF-1– or Cu-induced HIF-1α activation and VEGF expression. 
Western blot analysis shows that treatment of the cells with the CCS 
siRNA for 48 h silenced the CCS expression but mismatched siRNA 
(MMsiRNA) did not. After treatment with the CCS siRNA for 48 h, the cells 
were incubated with IGF-1 or Cu for 16 h. HIF-1α transcription activity 
was assayed using the cell lysate by an ELISA assay and VEGF concentra-
tions in culture media by an ELISA assay and normalized by cell numbers. 
CCS siRNA signifi  cantly suppressed the transcription activity of HIF-1α 
and VEGF expression. Values are mean ± SD (n = 6), and the experiment 
was repeated two times with consistent results. *, Signifi  cantly different 
from unstimulated control (P < 0.05, n = 6). #, Signifi  cantly different 
from corresponding mismatched RNA treated cultures (P < 0.05, n = 6).
Figure 9.  Effects of SOD1 siRNA on IGF-1– or Cu-induced VEGF 
expression. Treatment with SOD1 siRNA for 48 h silenced the SOD1 
expression but mismatched siRNA (MMsiRNA) did not (Western blot). 
After treatment with the SOD1 siRNA for 48 h, the cells were incubated 
with IGF-1 or Cu for 16 h. VEGF concentrations in culture media were 
measured by an ELISA assay and normalized by cell numbers. Values are 
mean ± SD (n = 6), and the experiment was repeated two times with 
consistent results.664  COPPER REVERSAL OF HYPERTROPHIC CARDIOMYOPATHY | Jiang et al.
Cu regulation of VEGF expression has been suggested in 
several studies (19–22). One study has shown that, at physio-
logic concentrations, Cu induces the synthesis of VEGF, 
which promotes angiogenesis in a healing wound (23). In 
Cu-defi  cient mouse hearts, generated by dietary Cu restric-
tion, VEGF expression was markedly depressed and Cu re-
pletion of the diet completely restored the expression of 
VEGF in the heart (22) along with regression of Cu defi  -
ciency–induced hypertrophic cardiomyopathy (24). The data 
presented here further demonstrate the link between Cu and 
VEGF production and the associated angiogenesis in the 
heart. Here, we have specifi  cally addressed the question of 
whether or not VEGF is necessary for the regression of 
  hypertrophic cardiomyopathy. The results clearly show that 
anti-VEGF antibody-mediated depletion of VEGF prevents 
Cu supplementation–induced reversal of hypertrophic car-
diomyopathy, demonstrating the necessary role of VEGF in 
the regression.
Is Cu required for VEGF expression in cardiomyocytes? 
Cu at physiologically relevant levels stimulated VEGF ex-
pression, which mimicked the eff  ect of IGF-1 in cultured 
human cardiomyocytes. The Cu chelator TEPA suppressed 
not only Cu-stimulated, but also IGF-1–induced VEGF pro-
duction, indicating that Cu is required for IGF-1–activated 
VEGF expression. Furthermore, the basal level of VEGF 
expression was also decreased in the TEPA-treated con-
trol cultures, and addition of excess Cu into TEPA treated 
cultures restored VEGF expression. Therefore, these results 
strongly indicate that Cu is essential for VEGF expression 
in cardiomyocytes.
How does Cu regulate VEGF expression? The results 
showed that HIF-1α was critically involved in the Cu regula-
tion of VEGF expression. The in vitro data that siRNA tar-
geting HIF-1α abolished Cu stimulation of VEGF expression 
demonstrate an essential role of HIF-1α in Cu-dependent 
VEGF expression in the heart. In the cell, there is virtually no 
free Cu (25), so that Cu chaperones direct Cu transport spe-
cifi  cally to its target molecules. For instance, CCS has been 
identifi  ed as a Cu chaperone for SOD1 (26). CCS interacts 
directly with SOD1 for the insertion of ionic Cu into the 
metalloprotein (25). This effi   cient Cu delivery mechanism 
avoids ineffi   cient and potentially dangerous traffi   cking of Cu 
within the cell. In this context, the interaction between Cu 
and HIF-1α could also be mediated by a Cu chaperone such 
as CCS. In fact, we found that CCS coimmunoprecipitated 
with HIF-1α. This is an important novel observation, as it 
indicates that CCS may not only transfer Cu ion to SOD1 
but to other proteins as well. It also indicates that a direct 
  interaction between CCS and the Cu requiring apoproteins 
may represent a common mechanism for Cu transfer in the 
cell. However, it is the Cu requiring apoproteins that deter-
mine the functional specifi  city. In this context, we have ex-
cluded the possible involvement of SOD1 in Cu regulation 
of VEGF by showing that SOD1 gene silencing did not 
  inhibit IGF-1– or Cu-stimulated VEGF expression. An un-
resolved issue is how Cu interacts with HIF-1α through CCS, 
a question that will require more extensive chemical and 
structural studies.
The result obtained from the use of siRNA targeting 
CCS demonstrated the importance of CCS in the regulation 
of Cu-activated HIF-1α transcription activity and VEGF 
  expression. The inhibitory eff  ect of CCS gene silencing on 
IGF-1–induced HIF-1α activation and VEGF expression was 
as the same as that of Cu chelator, TEPA. Since CCS is a Cu-
specifi  c chaperone, the CCS gene silencing result not only 
provides a mechanistic insight into Cu regulation of VEGF 
expression but also supports the conclusion obtained from 
the Cu chelator study for the essentiality of Cu in the regu-
lation of VEGF expression. The CCS gene silencing result 
also excludes a possible confounding eff  ect of nonspecifi  c 
metal chelation by TEPA on IGF-1–induced HIF-1α acti-
vation and VEGF expression.
This study for the fi  rst time presents evidence that Cu is 
required for HIF-1α activation and VEGF expression in car-
diomyocytes. Cu activation of HIF-1α is mediated by CCS, 
which appears to directly interact with HIF-1α. The results 
provide a scientifi  c rationale for Cu supplementation as a 
means of causing the regression of hypertrophic cardiomyop-
athy induced by sustained pressure overload. Should similar 
eff  ects of Cu supplementation be found in controlled studies 
in human patients, this will point the way to a simple, 
  nontoxic and extraordinarily economical therapy for hyper-
trophic cardiomyopathy.
MATERIALS AND METHODS
Animal models. Male C57BL/6J mice (10–12 wk old; The Jackson Labo-
ratory) were fed standard AIN-93 diet (27) containing 6 mg Cu/kg, which 
is the adequate level of Cu for mice according to the RDA established by 
Food and Nutritional Board of the Institute of Medicine (2) and is equivalent 
to current RDA for humans (0.9 mg Cu/day). Pressure overload was pro-
duced by AAC as described previously (28–30). In brief, mice were anesthe-
tized and ventilated with a rodent respirator. Aortic constriction was made 
through a left thoracotomy by placing a ligature using a 6-0 silk suture se-
curely around the ascending aorta and a 26 1/2– gauge blunted needle and 
then removing the needle. For the sham operation, the left thoracotomy was 
made but the aorta was not ligated. The animal survival rate due to the AAC 
surgery was 80% including postsurgical death. The animal procedure was 
approved by the Institutional Animal Care and Use Committee, which is 
certifi  ed by the American Association of Accreditation for Laboratory Ani-
mal Care.
4 wk after the AAC surgery, some mice were sacrifi  ced for analyses. 
One group of AAC mice was changed to a diet containing 20 mg Cu/kg, 
and the other group remained on the 6 mg Cu/kg diet. The supplementa-
tion level of Cu in the diet is equivalent to 2.9 mg Cu/day in humans, an in-
take easily reached if conventional multiple mineral and vitamin supplements 
are used (2 mg Cu/day plus RDA of 0.9 mg Cu/day). The mice were har-
vested for the analyses at either 4 or 8 wk after AAC. At the time of harvest-
ing, heart weight to body weight ratio and lung weight to body weight ratio 
were obtained. Although there were premature deaths of some AAC mice 
fed 6 mg Cu/kg diet for 8 wk, the number of mice for each parameter mea-
sured was six or greater.
Anti-VEGF treatment. Anti–mouse VEGF antibody (R&D Systems, 
Inc.), 20 μg in 200 μl PBS, was given every 3 d by intraperitoneal injection 
to some mice starting when the mice were switched to the 20 mg Cu/kg 
diet after feeding 6 mg Cu/kg diet for 4 wk in both AAC surgery and sham 
controls. The treatment lasted for 27 d.JEM VOL. 204, March 19, 2007  665
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Echocardiography. Two-dimensional images of the left ventricle were 
obtained from the apical four- and two-chamber views with a phased-array 
echocardiography (SONOS 1500 or 2500; Hewlett-Packard, Inc.) and a 
2.5-MHz transducer in anesthetized mice. The images were recorded on 
1/2-inch videotape for subsequent review and analysis. With the use of a 
commercially available microcomputer system (GTI; Freeland), the echo-
cardiograms were analyzed qualitatively and quantitatively for the development 
of regional LV wall motion abnormalities. Quantitative analysis was per-
formed by use of a centerline method that constructs 100 equidistant chords 
perpendicular to a line centered between digitized LV end- diastolic and 
end-systolic endocardial borders.
Cu concentrations in the heart. Total Cu concentrations were de-
termined in the heart using inductively coupled argon plasma emission 
spectroscopy (model 35608; Thermo ARL-VG Elemental) after lyophili-
zation and digestion of the tissues with nitric acid and hydrogen peroxide 
(31). To confi  rm the dietary Cu concentrations, a dry-ashing procedure 
was used. This procedure included dissolution of the residue in aqua 
regia and measurement by atomic absorption spectrophotometry (model 
503; PerkinElmer).
Assessment of morphology changes. Hearts were excised, washed with 
saline solution, and placed in 10% formalin. Hearts were cut transversely 
close to the apex to visualize the left and right ventricles. Several sections of 
heart (4–5-μm thick) were prepared and stained with hematoxylin and eosin 
for histopathology or sirius red for collagen deposition and visualized by light 
microscope. Capillaries were visualized in frozen left ventricle sections 
stained with antibodies to endothelial cell adhesion molecule–1 (PECAM-1 
or CD31) (Santa Cruz Biotechnology Inc.). The capillary density was 
  assessed by a computer-assisted image analyzer (SigmaScan Pro5.0; SPSS, 
Inc.). Three fi  elds at 200× magnifi  cation per heart were analyzed, and six 
mice in each group were examined for the calculation. For examination by 
electron microscopy, a tissue sample preparation procedure described previ-
ously (32) was used.
Cell culture studies. Human cardiac myocytes (HCMs) along with the 
culture medium were purchased from ScienCell Research Laboratories. The 
culture medium was composed of basal medium, 5% FBS, 1% cardiac myo-
cyte growth supplement, and 1% penicillin/streptomycin solution (ScienCell). 
Cells were maintained at 37°C in a 95% humidifi  ed air and 5% CO2. Before 
each experiment, monolayer HCMs were allowed to grow to 90% confl  u-
ence, and switched to low-serum medium (basal medium supplemented 
with 1% FBS) for 24 h, then exposed to 100 ng/ml IGF-1 (Sigma-Aldrich), 
25 μM CuSO4 (Sigma-Aldrich), or 25 μM TEPA (Sigma-Aldrich) in the 
low-serum medium, alone or in combination. The culture media were col-
lected for VEGF measurement, and cells were harvested and subjected to 
HIF-1 activity assay at 16 h after the treatment.
Gene silencing. siRNAs targeting human HIF-1α, CCS, and SOD1 and 
negative mismatched control siRNA were designed and synthesized by 
  Ambion. The siRNA sequences for HIF-1α were sense, G  G  C  C  U  C  U  G  U  G-
A  U  G  A  G  G  C  U  U  tt and antisense, A  A  G  C  C  U  C  A  U  C  A  C  A  G  A  G  G  C  C  tt. The 
siRNA sequences for CCS, sense, G  G  A  C  C  A  G  A  U  G  G  U  C  U  U  G  G  U  A  tt, and 
antisense, U  A  C  C  A  A  G  A  C  C  A  U  C  U  G  G  U  C  C  tt. A validated SOD1 siRNA 
was obtained from the same company (siRNA ID no.: 119429). After the 
monolayer HCM cultures reached 50% confl  uence, the cells were trans-
fected with 100 nM annealed siRNAs targeting specifi  c genes or negative 
mismatched siRNA using a Silencer siRNA transfection kit (Ambion) ac-
cording to the manufacturer’s instruction. At 48 h after the transfection, the 
culture media were changed to the low-serum medium for 24 hr, and then 
exposed to 100 ng/ml IGF-1 or 25 μM CuSO4 alone or in combination. 
Some cultures were exposed to 150 μM CoCl2 (Sigma-Aldrich) to increase 
HIF-1α levels. The culture media were collected for VEGF measurement, 
and cells were harvested and subjected to HIF-1 analysis at 16 h after the 
last treatment.
HIF-1 activity assay. The nuclear extracts of cultured cells were obtained 
by using a nuclear extract kit (Active Motif) according to the manufacturer’s 
instruction. HIF-1 activity was quantifi  ed in 5–10 μg of nuclear extracts by 
specifi  c binding of HIF-1 to an oligonucleotide containing the HRE from the 
EPO gene (5′-TACGTGCT-3′) using a TransAM HIF-1 transcription factor 
assay kit (Active Motif) following the manufacturer’s instruction. Each sample 
was measured in duplicate, and the measured activity was normalized to total 
protein content measured by a Bio-Rad Laboratories protein assay kit.
Quantitative analysis of VEGF. VEGF in culture media was measured 
using a Quantikine Human VEGF Immunoassay (R&D Systems) according 
to the manufacturer’s instruction. Each sample was measured in duplicate, 
and the VEGF concentrations were normalized by the number of cells in 
each culture sample.
Enzymatic assay for CCO. Mitochondria were isolated from fresh heart 
samples using a mitochondrial isolation kit (Pierce Chemical Co.) following 
the instruction provided. CCO was assayed as described previously (33). In 
brief, CCO was measured by adding ferrocytochrome c in an isosmotic 
  medium (10 mM KH2PO4, pH 6.5, 1 mg/ml bovine albumin, 0.3 M sucrose). 
The activity was calculated from the rate of decrease in absorbance of ferro-
cytochrome c at 550 nM (ε = 19.1 mM−1cm−1) and normalized by mito-
chondrial protein content. Because accurate estimations of CCO activity 
could be compromised by variations in mitochondrial yield and integrity, the 
CCO activity in the present study was normalized using an invariant marker 
of mitochondrial enzyme activity, citrate synthase. Citrate synthase was as-
sayed by following the reduction of 5,5′-dithio-bis(2-nitrobenzoic acid) 
(2 mM) in the presence of acetyl-CoA (0.1 mM) and oxalacetic acid (12 mM) 
in a medium containing 10 mM KH2PO4, pH 7.8, 2 mM EDTA, 1 mg/ml 
BSA, and 0.1% Triton X-100. The change in absorbance at 412 nm was 
monitored for 30 min (refl  ecting the formation of thionitrobenzoate). The 
citrate synthase activity was calculated from the change in   absorbance using 
ε = 13.6 mM−1cm−1, and normalized by mitochondrial protein content.
Immunoprecipitation analysis of CCS and HIF-1𝗂. HCM cell lysates 
were prepared in ice-cold IP buff  er containing 50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1% Triton X-100, 10% glycerol and protease inhibitor cock-
tail (Sigma-Aldrich). Crude cell lysates containing 300 μg protein were pre-
cleared by incubating with protein G–Sepharose 4FF (GE Healthcare) and 
mixed with 4 μg of rabbit anti-CCS antibody (FL-274; Santa Cruz Bio-
technology, Inc.) and incubated at 4°C overnight under rotation. 30 microliters 
of preequilibrated protein G–Sepharose 4FF were then added and incubated 
for 1 h at 4°C under rotation. After centrifugation at 1,000 g for 2 min, 
  supernatants were removed, and the beads were washed three times with the 
IP buff  er. The resulting immunocomplex-containing beads were treated 
with SDS sample buff  er and subjected to Western blot analysis.
Western blot analysis of proteins. The sample preparation from frozen 
mouse hearts and cultured cells, gel electrophoresis, and transfer to blotting 
membranes were described previously (34, 35). Nonspecifi  c binding was 
blocked by using a blocking buff   er (5% nonfat dry milk, Tris-buff  ered 
  saline: 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.5% Tween 20) for 2 h at 
room temperature, and then the blotting membranes were incubated over-
night at 4°C with the following primary antibodies diluted in blocking 
buff  er: rabbit anti–human SOD1 polyclonal antibody (1:1,000 Santa Cruz 
Biotechnology, Inc.), mouse anti–human HIF-1α monoclonal antibody 
(1  μg/ml; Sigma-Aldrich), goat anti–mouse VEGF polyclonal antibody 
(2 μg/ml; R&D Systems), rabbit anti–human CCS (1:2,000; Santa Cruz 
Biotechnology, Inc.), and mouse anti-GAPDH monoclonal antibody 
(1:5,000; StressGen Biotechnologies). The membranes were washed in 
Tris-buff  ered saline, 1% Tween 20 (TBST) and incubated for 2 h at room 
temperature with HRP-conjugated rabbit anti–goat IgG and goat anti–
mouse or rabbit IgG antibodies (1:20,000; Southern Biotechnology 
  Associates, Inc.) diluted in TBST. The blots were processed and visualized 
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Statistical analysis. Data were expressed as mean ± SD values and ana-
lyzed by ANOVA followed by a Duncan’s multiple-range test for further 
determination of the signifi  cance of diff  erences. Diff  erences among groups 
were considered signifi  cant when P < 0.05.
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